Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of Phase 2/3 randomized trials
J Am Acad Dermatol 2024;91:72–81 doi: 10.1016/j.jaad.2024.02.039
Results of this analysis by Blauvelt, et al. showed a low adjudicated suicidal ideation and behaviour (SIB) rate of 0.13/100 patient-years for bimekizumab, consistent with general psoriasis population ranges. Bimekizumab did not increase the risk of SIB compared to other anti-IL-17A/anti-IL-23 therapies.
The nine Phase 2/3 trials monitored mental health changes, including neuropsychiatric events using the patient-reported Columbia-Suicide Severity Rating Scale and Patient Health Questionnaire-9, with oversight by an independent Neuropsychiatric Adjudication Committee.
Keywords:
